CT引导下经皮穿刺置管硬化治疗卵巢巧克力囊肿的临床疗效分析

doi:10.3877/cma.j.issn.2095-5782.2022.04.009

目的

探讨CT引导下经皮穿刺置管硬化治疗卵巢巧克力囊肿的临床疗效与安全性。

方法

回顾性分析51例卵巢巧克力囊肿患者资料，其中8例经前腹壁穿刺置管，43例经臀部穿刺置管，随后经引流管注入聚桂醇泡沫硬化剂硬化治疗巧克力囊肿，分析治疗前后巧克力囊肿最大径、糖类抗原125（CA125）、抗缪勒管激素（AMH）变化情况及术后并发症情况。

结果

51例患者的整体有效率为98.0%。患者术后3、6个月的囊肿最大径均较术前显著性缩小（P值均< 0.001）；CA125水平均较术前显著性降低（P值均< 0.001）。患者术后6个月与术前、术后3个月的AMH水平差异均无统计学意义（P = 0.421，0.182）。无相关严重手术并发症出现。

结论

CT引导下经皮穿刺置管硬化治疗卵巢巧克力囊肿安全、有效，可作为较大（直径≥4 cm）卵巢巧克力囊肿的替代治疗方案。

关键词: CT, 卵巢巧克力囊肿, 硬化治疗, 疗效分析

Objective

To assessed the clinical effectiveness and safety of CT-guided percutaneous catheter-directed sclerotherapy (CDS) with lauromacrogol foam for ovarian endometriomas (OEM).

Methods

Of the 51 patients who underwent CDS for OEM were retrospectively analyzed, eight cases were punctured from the anterolateral abdominal wall, while 43 cases were punctured from buttock. Subsequently, lauromacrogol foam was injected into the cyst of OEM. Cyst size, serum cancer antigen 125 (CA-125), and serum anti-Müllerian hormone (AMH) levels were compared before and after the procedure. Operational complications were reviewed.

Results

The overall disease control rate of 51 patients was 98.0%. The mean size of cysts significantly decreased from before to after 3-months and 6-months of sclerotherapy (both P < 0.001). CA125 levels declined significantly from before to after 3-months and 6-months of sclerotherapy (both P < 0.001). There was no statistically significant difference between the after 6-months and preoperative or after 3-months of sclerotherapy AMH levels (P = 0.421, P = 0.182, respectively). There were no procedure-related seriously complications.

Conclusions

CT-guided percutaneous CDS for OEM is a safe, effective alternative to surgical intervention for treatment part of large diameter (≥4 cm) OEM.

Key words: CT, Sclerotherapy, Endometriosis, Efficacy

表1 51例卵巢巧克力囊肿基线情况

参数	未婚组（39例）	已婚组（12例）	P值
年龄（岁）	20~36（27）	22~38（27）	0.647
单侧囊肿（例）	28	6	0.166
双侧囊肿（例）	11	6
术前囊肿最大径（cm）	7.58 ± 2.65	5.97 ± 1.29	0.032
术前AMH（ng/mL）	2.98 ± 1.43	2.63 ± 2.04	0.230
术前CA125（U/mL）	80.06 ± 70.46	98.30 ± 111.95	0.965

表1 51例卵巢巧克力囊肿基线情况

参数	未婚组（39例）	已婚组（12例）	P值
年龄（岁）	20~36（27）	22~38（27）	0.647
单侧囊肿（例）	28	6	0.166
双侧囊肿（例）	11	6
术前囊肿最大径（cm）	7.58 ± 2.65	5.97 ± 1.29	0.032
术前AMH（ng/mL）	2.98 ± 1.43	2.63 ± 2.04	0.230
术前CA125（U/mL）	80.06 ± 70.46	98.30 ± 111.95	0.965

图1 CT引导下卵巢巧克力囊肿穿刺硬化治疗1A、1B：为经前腹壁穿刺置管硬化治疗前后；1C、1D：为经臀部穿刺置管硬化治疗前后

表2 51例患者治疗前后疗效指标变化情况

疗效指标	术前	术后3个月	术后6个月	P值*	P值**	P值***
囊肿最大径（cm）	7.20 ± 2.48	1.47 ± 1.73	1.44 ± 1.63	< 0.001	< 0.001	0.153
CA125（U/mL）	84.35 ± 81.19	24.10 ± 23.89	22.65 ± 19.48	< 0.001	< 0.001	0.705
AMH（ng/mL）	2.90 ± 1.58	2.30 ± 1.42	2.57 ± 1.42	0.028	0.421	0.182

表2 51例患者治疗前后疗效指标变化情况

疗效指标	术前	术后3个月	术后6个月	P值*	P值**	P值***
囊肿最大径（cm）	7.20 ± 2.48	1.47 ± 1.73	1.44 ± 1.63	< 0.001	< 0.001	0.153
CA125（U/mL）	84.35 ± 81.19	24.10 ± 23.89	22.65 ± 19.48	< 0.001	< 0.001	0.705
AMH（ng/mL）	2.90 ± 1.58	2.30 ± 1.42	2.57 ± 1.42	0.028	0.421	0.182

[1]	Llarena N C, Falcone T, Flyckt R L. Fertility Preservation in Women With Endometriosis[J]. Clin Med Insights Reprod Health, 2019, 13: 1179558119873386.
[2]	Brosens I, Gordts S, Puttemans P, et al. Pathophysiology proposed as the basis for modern management of the ovarian endometrioma[J]. Reprod Biomed Online, 2014, 28(2): 232-238.
[3]	Cohen A, Almog B, Tulandi T. Sclerotherapy in the management of ovarian endometrioma: systematic review and meta-analysis[J]. Fertil Steril, 2017, 108(1): 117-124.e5.
[4]	Galczynski K, Jozwik M, Lewkowicz D, et al. Ovarian endometrioma-a possible finding in adolescent girls and young women: a mini-review[J]. J Ovarian Res, 2019, 12(1): 104.
[5]	Hsieh CL, Shiau CS, Lo LM, et al. Effectiveness of ultrasound-guided aspiration and sclerotherapy with 95% ethanol for treatment of recurrent ovarian endometriomas[J]. Fertil Steril, 2009, 91(6): 2709-2713.
[6]	李龙, 张迪, 曾欣巧, 等. 制作1%聚桂醇泡沫硬化剂的最佳液-气比[J]. 介入放射学杂志, 2015(5): 418-421.
[7]	宋樟伟, 林玲玲, 赵雅萍, 等. 聚桂醇与无水乙醇治疗卵巢巧克力囊肿的临床疗效分析[J]. 浙江临床医学, 2017, 19(2): 251-252.
[8]	Kim ML, Cho YJ, Kim MK, et al. The efficacy of long-term maintenance therapy with a levonorgestrel-releasing intrauterine system for prevention of ovarian endometrioma recurrence[J]. Int J Gynaecol Obstet, 2016, 134(3): 256-259.
[9]	Benagiano G, Guo SW, Bianchi P, et al. Pharmacologic treatment of the ovarian endometrioma[J]. Expert Opin Pharmacother, 2016, 17(15): 2019-2031.
[10]	Grandi G, Barra F, Ferrero S, et al. Hormonal contraception in women with endometriosis: a systematic review[J]. Eur J Contracept Reprod Health Care, 2019, 24(1): 61-70.
[11]	Muzii L, Galati G, Di Tucci C, et al. Medical treatment of ovarian endometriomas: a prospective evaluation of the effect of dienogest on ovarian reserve, cyst diameter, and associated pain[J]. Gynecol Endocrinol, 2020, 36(1): 81-83.
[12]	Gordts S, Koninckx P, Brosens I. Pathogenesis of deep endometriosis[J]. Fertil Steril, 2017, 108(6): 872-885.e1.
[13]	Zakhari A, Edwards D, Ryu M, et al. Dienogest and the Risk of Endometriosis Recurrence Following Surgery: A Systematic Review and Meta-analysis[J]. J Minim Invasive Gynecol, 2020, 27(7): 1503-1510.
[14]	Huang L, Chang MY, Shiau CS, et al. Changes in anti-mullerian hormone after ultrasound guided aspiration and ethanol sclerotic therapy of ovarian cyst[J]. Taiwan J Obstet Gynecol, 2021, 60(3): 509-512.
[15]	Shin KH, Kim HH, Kwon BS, et al. Clinical usefulness of cancer antigen (CA) 125, human epididymis 4, and CA72-4 levels and risk of ovarian malignancy algorithm values for diagnosing ovarian tumors in Korean patients with and without endometriosis[J]. Ann Lab Med, 2020, 40(1): 40-47.
[16]	肖丽珍, 方锋凯, 陈开良. 超声引导下介入治疗对卵巢巧克力囊肿患者血清转录因子活化蛋白激酶B、糖类抗原125、白细胞介素-6的影响[J]. 介入放射学杂志, 2020, 29(11): 1131-1135.
[17]	Leone Roberti Maggiore U, Gupta JK, Ferrero S. Treatment of endometrioma for improving fertility[J]. Eur J Obstet Gynecol Reprod Biol, 2017, 209: 81-85.
[18]	Birch Petersen K, Hvidman HW, Forman JL, et al. Ovarian reserve assessment in users of oral contraception seeking fertility advice on their reproductive lifespan[J]. Hum Reprod, 2015, 30(10): 2364-2375.
[19]	Techatraisak K, Hestiantoro A, Ruey S, et al. Effectiveness of dienogest in improving quality of life in Asian women with endometriosis (ENVISIOeN): interim results from a prospective cohort study under real-life clinical practice[J]. BMC Womens Health, 2019, 19(1): 68.
[20]	Alborzi S, Zahiri Sorouri Z, Askari E, et al. The success of various endometrioma treatments in infertility: A systematic review and meta-analysis of prospective studies[J]. Reprod Med Biol, 2019, 18(4): 312-322.

[1]	魏淑婕, 惠品晶, 丁亚芳, 张白, 颜燕红, 周鹏, 黄亚波. 单侧颈内动脉闭塞患者行颞浅动脉-大脑中动脉搭桥术的脑血流动力学评估[J]. 中华医学超声杂志（电子版）, 2023, 20(10): 1046-1055.
[2]	韩丹, 王婷, 肖欢, 朱丽容, 陈镜宇, 唐毅. 超声造影与增强CT对儿童肝脏良恶性病变诊断价值的对比分析[J]. 中华医学超声杂志（电子版）, 2023, 20(09): 939-944.
[3]	张红霞, 程令刚, 汪洪斌, 张巍, 张雨康, 何文. 巨大肝囊肿无水乙醇硬化治疗后胆道损伤探讨[J]. 中华医学超声杂志（电子版）, 2023, 20(05): 487-491.
[4]	冉晨曦, 沈如飞, 廖明钰, 廖倩, 周玲, 张玉玲, 隆敏. 垂体瘤孕妇的诊治与围分娩期管理[J]. 中华妇幼临床医学杂志(电子版), 2023, 19(04): 487-491.
[5]	袁育韬, 邢金琳, 谢克飞, 殷凯. CT征象及BRAF^V600E基因突变与甲状腺乳头状癌中央区淋巴结转移的相关性[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 611-614.
[6]	周进军, 罗洪, 陈滔. 老年结直肠癌肺转移的CT特征及易发因素研究[J]. 中华普外科手术学杂志(电子版), 2023, 17(04): 398-400.
[7]	龙卫兵, 刘晓冰, 易仁政, 邹德博, 蒋玉斌, 陈亮, 谢超群, 刘红叶, 粟周华, 张雄峰, 李麒麟. CT、B超预定位"三步法"经皮肾镜治疗上尿路结石[J]. 中华腔镜泌尿外科杂志(电子版), 2023, 17(06): 587-592.
[8]	蒙姣姣, 胡刚, 欧阳涣堃. 肺癌术前淋巴结转移及MWA手术效果预测分析[J]. 中华肺部疾病杂志(电子版), 2023, 16(04): 547-549.
[9]	杨天池, 韩威, 邱枫, 祁佳慧. 术中胰腺超声弹性成像在胰腺质地评估中的应用[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 646-650.
[10]	王英, 薛意恒, 刘国勤. 肠系膜下动脉-高位结扎后降乙结肠血流通路重建机制研究方法的探索历程[J]. 中华结直肠疾病电子杂志, 2023, 12(04): 265-271.
[11]	陈科春, 吴秋义, 李建, 周寅, 徐周. 基于不同中性粒细胞与淋巴细胞比值探讨机械取栓术后首次CT征象与患者预后的关系[J]. 中华脑科疾病与康复杂志(电子版), 2023, 13(04): 215-221.
[12]	马丽. CT灌注联合血管成像预测急性脑梗死患者近期神经功能预后的价值分析[J]. 中华脑科疾病与康复杂志(电子版), 2023, 13(04): 229-234.
[13]	杨忠华, 马晓菡, 刁磊, 胡静, 陈熙. 双气囊小肠镜在小肠CT造影结果阴性患者中的诊断价值[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 475-479.
[14]	王佳凤, 郭锐, 陈倩倩, 李惠凯, 宁波, 袁新普, 朱华, 令狐恩强. ⁶⁸Ga-NC-BCH联合PET-CT淋巴结免疫示踪对于胃癌患者术前及术后临床决策影响的初步探索研究[J]. 中华胃肠内镜电子杂志, 2023, 10(04): 253-257.
[15]	李秦鹏, 王其涛, 朱媛媛, 周琦, 刘笑言, 许勇. 颈动脉彩色多普勒超声、颈部CT血管成像及脑部CT灌注成像在脑梗死并发颈动脉狭窄患者中的应用研究[J]. 中华脑血管病杂志(电子版), 2023, 17(05): 482-488.

阅读次数

全文

摘要

选择文件类型/文献管理软件名称

选择包含的内容

Clinical effectiveness analysis of CT-guided percutaneous catheter-directed sclerotherapy for ovarian endometriomas

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

Clinical effectiveness analysis of CT-guided percutaneous catheter-directed sclerotherapy for ovarian endometriomas